Grants will award researchers seeking to harness biomarkers to improve diagnosis, prognosis or treatment efficacy studies with access to Quanterix’ ultra-sensitive detection solutions
Billerica, Mass. – April 24, 2020 —Quanterix Corporation (NASDAQ: QTRX), a company digitizing analysis to advance the science of precision health, today announced a call for proposals for the Simoa® Success Grant Program. Designed to support United States-based investigators addressing basic or pre-clinical questions in Infectious Disease and Immunology, the Simoa® Success Grant Program will award up to seven winning proposals with access to Quanterix’ industry-leading biomarker analysis technology, assay kits and consumables to complete their research.
“We’ve always believed that innovation comes through collaboration and in uniting with the Powering Precision Health (PPH) ecosystem to advance critical COVID-19 research, we’ve realized there is enormous untapped utility for biomarkers to improve the way we see and respond to immunological diseases,” said Kevin Hrusovsky, Chief Executive Officer, President and Chairman, Quanterix and Founder, Powering Precision Health. “Our Simoa® technology brings exquisite and unmatched sensitivity and specificity to biomarker analysis, uniquely positioning us to fuel new breakthroughs in infectious disease and immunology. Through this grant program, we hope to catalyze disruptive ideas to help patients and precision health.”
Special consideration will be given to projects aimed at demonstrating a need for highly sensitive and specific protein detection to advance research related to the diagnosis, prognosis or treatment of diseases engaging the immune system. Applicants are encouraged to present a plan for sample analysis with Simoa® Assay Kits or a plan for development of a novel Simoa® assay utilizing the Quanterix SP-X® Imaging and Analysis System, a complete benchtop biomarker detection platform that offers true multiplex detection at both acute and baseline levels, and custom Simoa® Homebrew assay kits. As many as 130 samples may be submitted for analysis with one assay kit, or up to 65 samples may be submitted for analysis with two assay kits. All samples must be collected and stored by the applicant’s laboratory.
Upon the conclusion of the call for proposals, a Quanterix-designated review committee, composed of external reviewers, will select winning proposals based upon the novelty, feasibility, merit, and relevance to further work of the application addressed by the experimental design.
Grant Proposal 1:
One proposal will be awarded a placement of a Quanterix SP-X® Instrument, Simoa® Microplate Washer, and Simoa® Microplate Shaker, plus all necessary assay kits and consumables to run the proposed study. Awardee will be trained by a Quanterix Field Application Scientist and supported through completion of the study. Should the awardee commit to additional projects utilizing Simoa® assay kits, the instrument placement will be permanent.
Four proposals will be awarded free of charge sample analysis at Quanterix’ in-house, state-of-the-art CLIA certified Simoa® Accelerator Laboratory to complete the proposed study.
Grant Proposal 2: Two proposals will be awarded free of charge novel assay prototyping and sample analysis demonstrating proof of concept for use of the assay to achieve specific research goals. Awardee will provide antibodies, antigen and samples to Quanterix. Work will be completed at Quanterix headquarters, and all details of assay design will be shared with the awardee to enable future work based on the study.
Validated by more than 650 peer-reviewed publications, Quanterix is recognized throughout the industry as a world leader in biomarker detection. Operating at a sensitivity 1000 times greater than conventional ELISA platforms, Simoa® has the proven ability to see and quantify biomarkers at concentrations previously undetectable. This unprecedented sensitivity has empowered researchers to study disease in new ways, allowing for earlier detection, improved understanding and monitoring of disease pathology, and a more accurate assessment of experimental therapeutics. Today, researchers around the world are actively deploying this technology to combat COVID-19 by leveraging Simoa® technology to unlock critical insights into the immune response through its robust, multiplexed assays for measuring cytokines, chemokines and antibodies.
The grant is the latest installment in the company’s Grant Program. Established in 2016, the program has recognized innovative researchers across the country, including Shelli Kesler, Ph.D., and Ashley Henneghan, Ph.D., MSN, RN, from the School of Nursing at the University of Texas at Austin. Drs. Kesler and Henneghan won the most recent program for their proposal entitled, “Neurodegenerative and Inflammatory Predictors of Cancer Related Cognitive Impairment in Breast Cancer Patients,” which sought to evaluate the neurotoxic effect of chemotherapy in breast cancer patients.
This year’s recipients will be invited to present their findings of the grant-awarded research at Quanterix’ Simoa® Success Seminars Series in the Fall of 2020. This ongoing series aims to provide customers, partners and prospects with the latest Simoa® assay developments and platform applications.
To be considered for the grant, all interested parties must submit their proposals by 5 p.m. EDT on June 1, 2020. Recipients will be notified of their selection status by June 15, 2020.
Additional terms and conditions apply. To learn more and submit your Simoa® Success Grant Program proposal, click here.
Quanterix is a company that’s digitizing biomarker analysis with the goal of advancing the science of precision health. The company’s digital health solution, Simoa, has the potential to change the way in which healthcare is provided today by giving researchers the ability to closely examine the continuum from health to disease. Quanterix’ technology is designed to enable much earlier disease detection, better prognoses and enhanced treatment methods to improve the quality of life and longevity of the population for generations to come. The technology is currently being used for research applications in several therapeutic areas, including oncology, neurology, cardiology, inflammation and infectious disease. The company was established in 2007 and is located in Billerica, Massachusetts. For additional information, please visit https://www.quanterix.com.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "plan," "anticipate," "estimate," "intend" and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Forward-looking statements in this news release are based on Quanterix’ expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Factors that may cause Quanterix’ actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Quanterix’ filings with the U.S. Securities and Exchange Commission, including the "Risk Factors" sections contained therein. Except as required by law, Quanterix assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.
Staci Didner, (407) 734-7325
Investor Relations Contact: